

From: [REDACTED]
Sent: Tuesday 26 January 2021 15:08
To: [REDACTED]
Cc: [REDACTED]
Subject: FW: CALL FOR TENDERS SANTE/2020/C3/087 Exclusion
criteria evidence further request
Attachments: [REDACTED]

Categories: [REDACTED]

Dear [REDACTED],

This message is in response to your communication on [REDACTED]. Please see our responses are below:

2a. Evidence regarding situations of exclusion described in (a), (c), (d), (f), (g) and (h) of Part I of Annex 6 to the Tender Specifications

1. [REDACTED]

2b. Evidence regarding situations of exclusion described in (b) of Part I of Annex 6 to the Tender Specifications:

[REDACTED]

[REDACTED]

We believe that we are now current on the outstanding information due [REDACTED]. Please do advise if your accounting states differently.



21 Firstfield Road
Gaithersburg, MD 20878
Direct Line: [REDACTED]
Mobile: [REDACTED]
Email: [REDACTED]
www.novavax.com

From: [REDACTED]
Sent: Thursday, January 21, 2021 12:45 PM
To: [REDACTED]
Cc: [REDACTED]
Subject: CALL FOR TENDERS SANTE/2020/C3/087 – Exclusion criteria evidence further request

[SENDER IS EXTERNAL TO NOVAVAX]

Dear [REDACTED],

We refer to the requested evidence regarding the absence of situations of exclusion as described in the section VI of the Declaration of Honor (our request from 6 January 2021). Please find below the comments regarding the documents submitted by you on [REDACTED], **bearing however in mind that only the evaluation committee is entitled to provide the final assessment and endorsement:**

2a. Evidence regarding situations of exclusion described in (a), (c), (d), (f), (g) and (h) of Part I of Annex 6 to the Tender Specifications

■

[REDACTED]

2b. Evidence regarding situations of exclusion described in (b) of Part I of Annex 6 to the Tender Specifications:

■

[REDACTED]

■

In a situation where Novavax Inc. is [REDACTED] we would appreciate if you could provide as a response a statement to that fact.

We rest at your disposal in case of any questions or doubts.
Kind regards

[REDACTED]



European Commission
DG Health and Food Safety

[REDACTED]

From: [REDACTED]
Sent: Friday, January 8, 2021 4:21 PM
To: [REDACTED]
Cc: [REDACTED]
Subject: Fwd: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

Dear [REDACTED]

Please see the following email with attachments as follow up to your recent request. We look forward to any updates.

Kind Regards,

Novavax, INC.

Get [Outlook for iOS](#)

From: [REDACTED]
Sent: Friday, January 8, 2021 10:12 AM
To: [REDACTED]
Cc: [REDACTED]
Subject: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

Dear [REDACTED]

In response to the additional information you requested on [REDACTED], we are providing the following in hopes that it meets your needs:

1. [REDACTED]

2a. Evidence regarding situations of exclusion described in (a), (c), (d), (f), (g) and (h) of Part I of Annex 6 to the Tender Specifications

1. [REDACTED]

2b. Evidence regarding situations of exclusion described in (b) of Part I of Annex 6 to the Tender Specifications:

2. [REDACTED]

3. [REDACTED]

Confidentiality Note

Please be advised that Novavax, Inc. (together with its subsidiaries "Novavax") is providing this proposal solely for the European Commission ("EC") to use in the call for tenders SANTE/2020/C3/087 - for the development, production, priority-purchasing options and supply of COVID-19 Vaccines for EU Member States (the "Project") and with the understanding that proposal contents will be treated as confidential. The information included in this proposal is confidential and/or private internal information of Novavax and its suppliers that is commercially sensitive and valuable. In accordance

with the EC's procedures and relevant European Union law, we hereby request confidential treatment of all of the materials included in the proposal

Cheers,

NOVAVAX
Creating Tomorrow's Vaccines Today

22 Firstfield Road
Gaithersburg, MD 20878
Mobile: [REDACTED]
Email: [REDACTED]
www.novavax.com

From: [REDACTED]
Sent: Wednesday, January 6, 2021 10:41 AM
To: [REDACTED]
Cc: [REDACTED]
Subject: RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

[REDACTED]

Dear [REDACTED],

After a first review of the documents submitted by Novavax Inc. it seems that we are missing the following elements:

1. Evidence regarding the financial and economic capacity F1 [REDACTED]
[REDACTED] as described in section 3.2.2. of the Tender Specifications.
2. Evidence regarding the [REDACTED] as described in the section VI of the [REDACTED]
[REDACTED]
 1. As evidence regarding situations of exclusion described in (a), (c), (d), (f), (g) and (h) of Part I of Annex 6 to the Tender Specifications:
[REDACTED]

- [REDACTED]
2. **As evidence regarding situations of exclusion described in (b) of Part I of Annex 6 to the Tender Specifications:**
- [REDACTED]

Please note that this is a first, general review of your submission, and we might come back to you with further requests following the assessment by the evaluation committee.

We remain at your disposal in case of any doubts or questions regarding the request.

Kind regards

[REDACTED]



European Commission
DG Health and Food Safety

[REDACTED]